Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach

Published
24 Mar 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$7.27
14.8% undervalued intrinsic discount
08 Aug
US$6.19
Loading
1Y
-77.9%
7D
55.5%

Author's Valuation

US$7.3

14.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 53%

Shared on24 Apr 25
Fair value Increased 103%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 56%

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 2.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 135%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.